Insider · CIK 0001793796
David Hollander
officerdirector
Files at KPRX (KIORA PHARMACEUTICALS INC), RVNC (Revance Therapeutics, Inc.), MANE (Veradermics, Inc). First filing Nov 19, 2024, latest Nov 19, 2024.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $16k sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | RVNCsell Revance Therapeutics, Inc. | $16k 3,908 shares | -4% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | MANE Veradermics, Inc | AGrant or award Common Stock | +9,650 | $0.00 | $0 | 9,650 | 39 d ago |
| Sep 1, 2026 | MANE Veradermics, Inc | AGrant or award Stock Option (Right to Buy)derivative | +19,300 | $0.00 | $0 | 19,300 | 39 d ago |
| Apr 1, 2025 | KPRX KIORA PHARMACEUTICALS INC | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Apr 2, 2025 |
| Feb 4, 2025 | RVNC Revance Therapeutics, Inc. | UTender of shares Common Stock | -9,733 | $3.65 | $36k | 95,212 | Feb 6, 2025 |
| Feb 6, 2025 | RVNC Revance Therapeutics, Inc. | DDisposition to issuer Common Stock | -95,212 | - | - | 0 | Feb 6, 2025 |
| Nov 18, 2024 | RVNC Revance Therapeutics, Inc. | SOpen-market sale Common Stock | -3,908 | $4.17 | $16k | 104,945 | Nov 19, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.